The world's first once-weekly basal insulin, ‘Awiqli’

• A new milestone in diabetes treatment was achieved in India on July 9, 2026, with the launch of 'Awiqli'—the world's first once-weekly basal insulin.

• This drug is manufactured and marketed by the Danish pharmaceutical company Novo Nordisk and contains 'Insulin Icodec' as its active ingredient.

• It has received approval in India for the treatment of adult patients suffering from Type 1 and Type 2 diabetes.

• The primary advantage of Awiqli is that patients no longer need to administer basal insulin daily, as the medication is taken only once a week.

• This simplifies the treatment process and reduces the burden associated with frequent injections.

• The drug is administered via a 'FlexTouch' pen, making it easy to use.

• The Insulin Icodec within the drug binds to the body's blood albumin protein and activates gradually, allowing its effect to last for approximately seven days.

• In India, a 700-unit pack of Awiqli has been made available at a price of ₹2,611.

• According to the company, the cost per unit is approximately 30–40 percent lower than that of currently used daily basal insulins, potentially making it a more affordable option for patients.